Figure 1. .
Percentage of change in neovascular area (A), invasion area (B), total vessel length (C), and average vessel caliber (D) in response to topical pazopanib at the studied time points. At the end of follow-up period the mean reduction was 22.4% (mean ± SE [1.5 ± 0.8 mm2; P = 0.03]) for neovascular area, 13.3% (3.9 ± 1.8 mm2; P = 0.04) for invasion area, 23.9% (38.0 ± 17.2 mm; P < 0.01) for vessel length, and 2.3% (0.0003 ± 0.0005 mm; P = 0.62) for vessel caliber. Reduction of neovascularization was statistically significant for all metrics except for vessel caliber. Wk, weeks.